MAPT and Alzheimer disease: We recently presented the promising blood-based neurodegeneration biomarker brain-derived tau (BD-tau) that showed higher levels in biomarker-confirmed AD versus non-AD dementia and unaffected controls, including in a cohort with autopsy-verification of diagnosis and in memory clinic cohorts with large heterogeneity of disorders23.